详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China [2]South Sichuan Institute of Translational Medicine, Luzhou, 646000, Sichuan, China [3]Department of Oncology and Hematology, Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, 646000, Sichuan, China [4]Department of Gastrointestinal Surgery, Hospital Affiliated to Southwest Medical University, Luzhou, 646000, Sichuan, China [5]Department of Obstetrics and Gynecology, Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, 646000, Sichuan, China [6]Department of Oncology, Hospital Affiliated to Southwest Medical University, Luzhou, 646000, Sichuan, China [7]School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China

出处：

DOI：

ISSN：

关键词： Natural killer cells Cancer immunotherapy Chimeric antigen receptor Antibody dependent cell-mediated cytotoxicity

摘要：

Natural killer (NK) cells are immune cells which are able to kill tumor and virus-infected cells and play an important role in both innate immunity and acquired immunity. Tumor immunotherapy is an emerging model of tumor treatment in the clinic. It is a re-emerging type of anticancer immunotherapy with the purpose of killing tumor cells by modulating the body's immune function and enhancing the antitumor immunity in tumor microenvironment. At present, many immune cells including lymphokine-activated killer cells, NK cells, cytokine-induced killer cells, and dendritic cells are involved in tumor immunotherapy studies. NK cells, which lyse tumor cells without prior stimulation, has become a research hotspot in cancer immunotherapy for clinical application. In this article, we discussed the surface receptors of NK cells and the anticancer function of NK cells. We also reviewed the biological characteristics and the current research status of NK cells, their clinical application in cancer immunotherapy and its future perspectives. Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版中科院分区表Review为是的期刊

：

大类 | 2 区医学

小类 | 2 区药学

最新[2023]版：

大类 | 2 区

医学

小类 | 1 区药学

第一作者：

第一作者机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China [2]South Sichuan Institute of Translational Medicine, Luzhou, 646000, Sichuan, China

共同第一作者：

通讯作者：

通讯机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China [2]South Sichuan Institute of Translational Medicine, Luzhou, 646000, Sichuan, China [*1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential [2]嵌合抗原受体自然杀伤细胞免疫治疗多发性骨髓瘤研究进展 [3]A compound chimeric antigen receptor strategy for targeting multiple myeloma. [4]New Approaches in CAR-T Cell Immunotherapy for Breast Cancer [5]Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo. [6]Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo. [7]Requirements for human natural killer cells [8]GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction. [9]Research advances in chimeric antigen receptor-modified T-cell therapy (Review). [10]Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy